In another twist to the Aduhelm approval tale, FDA's Janet Woodcock has called for an independent investigation into the relationship between agency staffers and Biogen executives.
One of the criticisms levelled at the FDA over its approval of Biogen and Eisai's Alzheimer's disease drug Aduhelm was its decision to clear use of the drug in a broader group of patients t
Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer's therapy Aduhelm – but only if its assumptions on population size and uptake are differe
Japan's Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing deal from Bristol-Myers Squibb that could top out at more than $3.
Merck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a survival benefit in a confirmatory phase 3 trial.
New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the increasingly competitive first-line kidney cancer market.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.